Docket #: S22-327
Ibogaine for Treatment of Brain Disorders
Stanford researchers at Dr. Williams' Brain Stimulation Lab have developed a method to treat brain disorders such as traumatic brain injury using a naturally occurring psychoactive molecule found in plants called Ibogaine. Ibogaine is found in the family Apocynaceae, most familiarly in Tabernanthe iboga.
This new method employs the potential positive effect of ibogaine or ibogaine with hERG stabilizing agents, on mood and brain function to treat traumatic brain injury and operator syndrome as well as other brain disorders such as PTSD, Addiction, Depression, or Alzheimer's.
Additional disclosures from the Brain Stimulation Lab, Stanford dockets S22-450 and S23-045, describe methods for mitigating health risks of Ibogaine by using hERG stabilizing agents.
Stage of Development
Open label trial completed
Applications
- Treatment of brain disorders including but not limited to: Traumatic brain injury/Operator Syndrome, PTSD, Addiction, Depression, and Alzheimer's
Advantages
- Novel use of Ibogaine for brain treatment
- Safer application due to use of HERG stabilizing agents
Related Links
Patents
- Published Application: 20240100062
- Published Application: WO2024059713
- Published Application: 20240100061
- Published Application: WO2024059717
Similar Technologies
-
Dopamine2 Specific Promoter S14-310Dopamine2 Specific Promoter
-
Efficient Microglia Replacement without Genetic Modification via Bone-Marrow Derived Cells S20-137Efficient Microglia Replacement without Genetic Modification via Bone-Marrow Derived Cells
-
Genetically-Targetable Optical Inactivation of Excitable Cells S06-398AGenetically-Targetable Optical Inactivation of Excitable Cells